Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Mayo Clinic, Jacksonville, Florida, United States.
Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, Minnesota, United States.
J Gastrointestin Liver Dis. 2020 Dec 13;29(4):629-635. doi: 10.15403/jgld-2990.
The use of statins has been shown to be associated with a decreased risk of cholangiocarcinoma (CCA) in many studies although the results have been inconsistent. We conducted this systematic review and meta-analysis to further investigate this possible association by identifying all relevant studies and combining their results together.
A comprehensive literature review was conducted utilizing the MEDLINE and EMBASE databases through March 2020 to identify all studies that compared the risk of CCA among individuals who use statins with individuals who do not use statins. Effect estimates from each study were extracted and combined using the random-effect, generic inverse variance method of DerSimonian and Laird.
A total of seven studies with 6,251,187 participants fulfilled the eligibility criteria and were included in this meta-analysis. The pooled analysis found a significantly decreased risk of CCA among individuals who use statins compared with individuals who do not use statins with the pooled odds ratio of 0.68 (95% CI: 0.52-0.89; I 2 96%).
The current systematic review and meta-analysis found a significant association between the use of statins and a decreased risk of CCA.
许多研究表明，使用他汀类药物与胆管癌（CCA）风险降低相关，尽管结果不一致。我们进行了这项系统评价和荟萃分析，通过确定所有相关研究并将其结果合并在一起，进一步探讨这种可能的关联。
通过检索 MEDLINE 和 EMBASE 数据库，全面检索截至 2020 年 3 月的所有比较使用他汀类药物与未使用他汀类药物的个体之间 CCA 风险的研究。从每项研究中提取效应估计值，并使用 DerSimonian 和 Laird 的随机效应、通用倒数方差法进行合并。
共有 7 项研究，涉及 6251187 名参与者，符合纳入标准并纳入本荟萃分析。汇总分析发现，与未使用他汀类药物的个体相比，使用他汀类药物的个体 CCA 风险显著降低，汇总比值比为 0.68（95%CI：0.52-0.89；I 2 96%）。
本系统评价和荟萃分析发现，使用他汀类药物与 CCA 风险降低之间存在显著关联。
